Tofflon Science and Technology Group (300171) Fundamentals 2026 — P/E 44.0x, Revenue Analysis | SniperIQ
Tofflon Science and Technology Group (300171) is a CN-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥8.9B, trading at ¥11.70 on the SHZ. This SniperIQ fundamentals page covers Tofflon Science and Technology Group's valuation (P/E 44.0x, P/B 1.1x), profitability (net margin 4.0%), revenue (¥5.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tofflon Science and Technology Group's market cap?
Tofflon Science and Technology Group (300171) has a market capitalization of approximately ¥8.9B, trading at ¥11.70 on the SHZ. Market cap moves with the live share price.
What is Tofflon Science and Technology Group's P/E ratio?
Tofflon Science and Technology Group's trailing twelve-month P/E ratio is 44.0x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tofflon Science and Technology Group?
Tofflon Science and Technology Group runs a net profit margin of 4.0%, a gross margin of 29.1%, and an operating margin of 5.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Tofflon Science and Technology Group generate?
Tofflon Science and Technology Group reported revenue of ¥5.2B for fiscal year 2025, with net income of ¥200M and earnings per share (EPS) of 0.26. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Tofflon Science and Technology Group pay a dividend?
Tofflon Science and Technology Group offers a trailing dividend yield of about 0.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Tofflon Science and Technology Group financially healthy?
Tofflon Science and Technology Group carries a debt-to-equity ratio of 0.01x and a current ratio of 1.98x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tofflon Science and Technology Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tofflon Science and Technology Group (300171) the key facts are: market cap ¥8.9B, P/E 44.0x, revenue ¥5.2B, 52-week range 10.42-20.37. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Tofflon Science and Technology Group's full fundamentals live
Get Tofflon Science and Technology Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.